English
简体中文
Total: £ 56.28
Published Date: 2026-02-06 | Pages: 126 | Tables: 119 | Pharma & Healthcare
The global Psoriasis Biosimilar market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Psoriasis Biosimilar competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
A psoriasis biosimilar refers to a biologic drug that is highly similar to an existing FDA-approved biologic treatment (the reference product) used for treating psoriasis, a chronic autoimmune condition that causes rapid skin cell turnover, leading to scales and inflamed patches of skin. Biosimilars are developed after the original biologic's patent expires and are designed to be equally effective, safe, and of the same high quality as the original.
The North American market for Psoriasis Biosimilar is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Psoriasis Biosimilar is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Psoriasis Biosimilar include Merck KGaA, Gyros Protein Technologies AB, Pfizer Inc., Novartis International AG, Amgen Inc, Samsung Bioepis Co., Ltd., Coherus BioSciences, Hoffmann-La Roche Ltd, Celltrion, Samsung Bioepis, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Psoriasis Biosimilar market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Psoriasis Biosimilar. The Psoriasis Biosimilar market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Psoriasis Biosimilar market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Psoriasis Biosimilar manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Merck KGaA
Gyros Protein Technologies AB
Pfizer Inc.
Novartis International AG
Amgen Inc
Samsung Bioepis Co., Ltd.
Coherus BioSciences
Hoffmann-La Roche Ltd
Celltrion
Samsung Bioepis
Sandoz
Fresenius Kabi
Viatris
Reddy's Laboratories
GenScript
Segment by Type
TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
Other Biosimilars
by Application
Plaque Psoriasis
Psoriatic Arthritis
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Psoriasis Biosimilar manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Psoriasis Biosimilar sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Psoriasis Biosimilar Market Overview
1.1 Product Definition
1.2 Psoriasis Biosimilar by Type
1.2.1 Global Psoriasis Biosimilar Market Value by Type: 2025 vs 2032
1.2.2 TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
1.2.3 Other Biosimilars
1.3 Psoriasis Biosimilar by Application
1.3.1 Global Psoriasis Biosimilar Market Value by Application: 2025 vs 2032
1.3.2 Plaque Psoriasis
1.3.3 Psoriatic Arthritis
1.3.4 Other
1.4 Global Psoriasis Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Psoriasis Biosimilar Revenue 2021–2032
1.4.2 Global Psoriasis Biosimilar Sales 2021–2032
1.4.3 Global Psoriasis Biosimilar Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Psoriasis Biosimilar Market Competition by Manufacturers
2.1 Global Psoriasis Biosimilar Sales Market Share by Manufacturers (2021–2026)
2.2 Global Psoriasis Biosimilar Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Psoriasis Biosimilar Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Psoriasis Biosimilar, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Psoriasis Biosimilar, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Psoriasis Biosimilar, Product Types and Applications
2.7 Global Key Manufacturers of Psoriasis Biosimilar, Date of Entry into the Industry
2.8 Global Psoriasis Biosimilar Market Competitive Situation and Trends
2.8.1 Global Psoriasis Biosimilar Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Psoriasis Biosimilar Players Market Share by Revenue
2.8.3 Global Psoriasis Biosimilar Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Psoriasis Biosimilar Market Scenario by Region
3.1 Global Psoriasis Biosimilar Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Psoriasis Biosimilar Sales by Region: 2021–2032
3.2.1 Global Psoriasis Biosimilar Sales by Region: 2021–2026
3.2.2 Global Psoriasis Biosimilar Sales by Region: 2027–2032
3.3 Global Psoriasis Biosimilar Revenue by Region: 2021–2032
3.3.1 Global Psoriasis Biosimilar Revenue by Region: 2021–2026
3.3.2 Global Psoriasis Biosimilar Revenue by Region: 2027–2032
3.4 North America Psoriasis Biosimilar Market Facts & Figures by Country
3.4.1 North America Psoriasis Biosimilar Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Psoriasis Biosimilar Sales by Country (2021–2032)
3.4.3 North America Psoriasis Biosimilar Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Psoriasis Biosimilar Market Facts & Figures by Country
3.5.1 Europe Psoriasis Biosimilar Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Psoriasis Biosimilar Sales by Country (2021–2032)
3.5.3 Europe Psoriasis Biosimilar Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Psoriasis Biosimilar Market Facts & Figures by Region
3.6.1 Asia Pacific Psoriasis Biosimilar Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Psoriasis Biosimilar Sales by Region (2021–2032)
3.6.3 Asia Pacific Psoriasis Biosimilar Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Psoriasis Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Psoriasis Biosimilar Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Psoriasis Biosimilar Sales by Country (2021–2032)
3.7.3 Latin America Psoriasis Biosimilar Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Psoriasis Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Psoriasis Biosimilar Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Psoriasis Biosimilar Sales by Country (2021–2032)
3.8.3 Middle East and Africa Psoriasis Biosimilar Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Psoriasis Biosimilar Sales by Type (2021–2032)
4.1.1 Global Psoriasis Biosimilar Sales by Type (2021–2026)
4.1.2 Global Psoriasis Biosimilar Sales by Type (2027–2032)
4.1.3 Global Psoriasis Biosimilar Sales Market Share by Type (2021–2032)
4.2 Global Psoriasis Biosimilar Revenue by Type (2021–2032)
4.2.1 Global Psoriasis Biosimilar Revenue by Type (2021–2026)
4.2.2 Global Psoriasis Biosimilar Revenue by Type (2027–2032)
4.2.3 Global Psoriasis Biosimilar Revenue Market Share by Type (2021–2032)
4.3 Global Psoriasis Biosimilar Price by Type (2021–2032)
5 Segment by Application
5.1 Global Psoriasis Biosimilar Sales by Application (2021–2032)
5.1.1 Global Psoriasis Biosimilar Sales by Application (2021–2026)
5.1.2 Global Psoriasis Biosimilar Sales by Application (2027–2032)
5.1.3 Global Psoriasis Biosimilar Sales Market Share by Application (2021–2032)
5.2 Global Psoriasis Biosimilar Revenue by Application (2021–2032)
5.2.1 Global Psoriasis Biosimilar Revenue by Application (2021–2026)
5.2.2 Global Psoriasis Biosimilar Revenue by Application (2027–2032)
5.2.3 Global Psoriasis Biosimilar Revenue Market Share by Application (2021–2032)
5.3 Global Psoriasis Biosimilar Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Merck KGaA
6.1.1 Merck KGaA Company Information
6.1.2 Merck KGaA Description and Business Overview
6.1.3 Merck KGaA Psoriasis Biosimilar Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Merck KGaA Psoriasis Biosimilar Product Portfolio
6.1.5 Merck KGaA Recent Developments/Updates
6.2 Gyros Protein Technologies AB
6.2.1 Gyros Protein Technologies AB Company Information
6.2.2 Gyros Protein Technologies AB Description and Business Overview
6.2.3 Gyros Protein Technologies AB Psoriasis Biosimilar Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Gyros Protein Technologies AB Psoriasis Biosimilar Product Portfolio
6.2.5 Gyros Protein Technologies AB Recent Developments/Updates
6.3 Pfizer Inc.
6.3.1 Pfizer Inc. Company Information
6.3.2 Pfizer Inc. Description and Business Overview
6.3.3 Pfizer Inc. Psoriasis Biosimilar Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Pfizer Inc. Psoriasis Biosimilar Product Portfolio
6.3.5 Pfizer Inc. Recent Developments/Updates
6.4 Novartis International AG
6.4.1 Novartis International AG Company Information
6.4.2 Novartis International AG Description and Business Overview
6.4.3 Novartis International AG Psoriasis Biosimilar Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Novartis International AG Psoriasis Biosimilar Product Portfolio
6.4.5 Novartis International AG Recent Developments/Updates
6.5 Amgen Inc
6.5.1 Amgen Inc Company Information
6.5.2 Amgen Inc Description and Business Overview
6.5.3 Amgen Inc Psoriasis Biosimilar Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Amgen Inc Psoriasis Biosimilar Product Portfolio
6.5.5 Amgen Inc Recent Developments/Updates
6.6 Samsung Bioepis Co., Ltd.
6.6.1 Samsung Bioepis Co., Ltd. Company Information
6.6.2 Samsung Bioepis Co., Ltd. Description and Business Overview
6.6.3 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Product Portfolio
6.6.5 Samsung Bioepis Co., Ltd. Recent Developments/Updates
6.7 Coherus BioSciences
6.7.1 Coherus BioSciences Company Information
6.7.2 Coherus BioSciences Description and Business Overview
6.7.3 Coherus BioSciences Psoriasis Biosimilar Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Coherus BioSciences Psoriasis Biosimilar Product Portfolio
6.7.5 Coherus BioSciences Recent Developments/Updates
6.8 Hoffmann-La Roche Ltd
6.8.1 Hoffmann-La Roche Ltd Company Information
6.8.2 Hoffmann-La Roche Ltd Description and Business Overview
6.8.3 Hoffmann-La Roche Ltd Psoriasis Biosimilar Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Hoffmann-La Roche Ltd Psoriasis Biosimilar Product Portfolio
6.8.5 Hoffmann-La Roche Ltd Recent Developments/Updates
6.9 Celltrion
6.9.1 Celltrion Company Information
6.9.2 Celltrion Description and Business Overview
6.9.3 Celltrion Psoriasis Biosimilar Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Celltrion Psoriasis Biosimilar Product Portfolio
6.9.5 Celltrion Recent Developments/Updates
6.10 Samsung Bioepis
6.10.1 Samsung Bioepis Company Information
6.10.2 Samsung Bioepis Description and Business Overview
6.10.3 Samsung Bioepis Psoriasis Biosimilar Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Samsung Bioepis Psoriasis Biosimilar Product Portfolio
6.10.5 Samsung Bioepis Recent Developments/Updates
6.11 Sandoz
6.11.1 Sandoz Company Information
6.11.2 Sandoz Description and Business Overview
6.11.3 Sandoz Psoriasis Biosimilar Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Sandoz Psoriasis Biosimilar Product Portfolio
6.11.5 Sandoz Recent Developments/Updates
6.12 Fresenius Kabi
6.12.1 Fresenius Kabi Company Information
6.12.2 Fresenius Kabi Description and Business Overview
6.12.3 Fresenius Kabi Psoriasis Biosimilar Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Fresenius Kabi Psoriasis Biosimilar Product Portfolio
6.12.5 Fresenius Kabi Recent Developments/Updates
6.13 Viatris
6.13.1 Viatris Company Information
6.13.2 Viatris Description and Business Overview
6.13.3 Viatris Psoriasis Biosimilar Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Viatris Psoriasis Biosimilar Product Portfolio
6.13.5 Viatris Recent Developments/Updates
6.14 Reddy's Laboratories
6.14.1 Reddy's Laboratories Company Information
6.14.2 Reddy's Laboratories Description and Business Overview
6.14.3 Reddy's Laboratories Psoriasis Biosimilar Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Reddy's Laboratories Psoriasis Biosimilar Product Portfolio
6.14.5 Reddy's Laboratories Recent Developments/Updates
6.15 GenScript
6.15.1 GenScript Company Information
6.15.2 GenScript Description and Business Overview
6.15.3 GenScript Psoriasis Biosimilar Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 GenScript Psoriasis Biosimilar Product Portfolio
6.15.5 GenScript Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Psoriasis Biosimilar Industry Chain Analysis
7.2 Psoriasis Biosimilar Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Psoriasis Biosimilar Production Mode & Process Analysis
7.4 Psoriasis Biosimilar Sales and Marketing
7.4.1 Psoriasis Biosimilar Sales Channels
7.4.2 Psoriasis Biosimilar Distributors
7.5 Psoriasis Biosimilar Customer Analysis
8 Psoriasis Biosimilar Market Dynamics
8.1 Psoriasis Biosimilar Industry Trends
8.2 Psoriasis Biosimilar Market Drivers
8.3 Psoriasis Biosimilar Market Challenges
8.4 Psoriasis Biosimilar Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Psoriasis Biosimilar Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Psoriasis Biosimilar Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Psoriasis Biosimilar Market Competitive Situation by Manufacturers in 2025
Table 4. Global Psoriasis Biosimilar Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Psoriasis Biosimilar Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Psoriasis Biosimilar Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Psoriasis Biosimilar Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Psoriasis Biosimilar Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Psoriasis Biosimilar, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Psoriasis Biosimilar, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Psoriasis Biosimilar, Product Types and Applications
Table 12. Global Key Manufacturers of Psoriasis Biosimilar, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Psoriasis Biosimilar Companies by Tier (Tier 1, Tier 2, Tier 3), based on Psoriasis Biosimilar Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Psoriasis Biosimilar Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Psoriasis Biosimilar Sales by Region (K Units), 2021–2026
Table 18. Global Psoriasis Biosimilar Sales Market Share by Region (2021–2026)
Table 19. Global Psoriasis Biosimilar Sales by Region (K Units), 2027–2032
Table 20. Global Psoriasis Biosimilar Sales Market Share by Region (2027–2032)
Table 21. Global Psoriasis Biosimilar Revenue by Region (US$ Million), 2021–2026
Table 22. Global Psoriasis Biosimilar Revenue Market Share by Region (2021–2026)
Table 23. Global Psoriasis Biosimilar Revenue by Region (US$ Million), 2027–2032
Table 24. Global Psoriasis Biosimilar Revenue Market Share by Region (2027–2032)
Table 25. North America Psoriasis Biosimilar Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Psoriasis Biosimilar Sales by Country (K Units), 2021–2026
Table 27. North America Psoriasis Biosimilar Sales by Country (K Units), 2027–2032
Table 28. North America Psoriasis Biosimilar Revenue by Country (US$ Million), 2021–2026
Table 29. North America Psoriasis Biosimilar Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Psoriasis Biosimilar Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Psoriasis Biosimilar Sales by Country (K Units), 2021–2026
Table 32. Europe Psoriasis Biosimilar Sales by Country (K Units), 2027–2032
Table 33. Europe Psoriasis Biosimilar Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Psoriasis Biosimilar Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Psoriasis Biosimilar Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Psoriasis Biosimilar Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Psoriasis Biosimilar Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Psoriasis Biosimilar Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Psoriasis Biosimilar Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Psoriasis Biosimilar Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Psoriasis Biosimilar Sales by Country (K Units), 2021–2026
Table 42. Latin America Psoriasis Biosimilar Sales by Country (K Units), 2027–2032
Table 43. Latin America Psoriasis Biosimilar Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Psoriasis Biosimilar Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Psoriasis Biosimilar Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Psoriasis Biosimilar Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Psoriasis Biosimilar Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Psoriasis Biosimilar Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Psoriasis Biosimilar Revenue by Country (US$ Million), 2027–2032
Table 50. Global Psoriasis Biosimilar Sales (K Units) by Type (2021–2026)
Table 51. Global Psoriasis Biosimilar Sales (K Units) by Type (2027–2032)
Table 52. Global Psoriasis Biosimilar Sales Market Share by Type (2021–2026)
Table 53. Global Psoriasis Biosimilar Sales Market Share by Type (2027–2032)
Table 54. Global Psoriasis Biosimilar Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Psoriasis Biosimilar Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Psoriasis Biosimilar Revenue Market Share by Type (2021–2026)
Table 57. Global Psoriasis Biosimilar Revenue Market Share by Type (2027–2032)
Table 58. Global Psoriasis Biosimilar Price (US$/Unit) by Type (2021–2026)
Table 59. Global Psoriasis Biosimilar Price (US$/Unit) by Type (2027–2032)
Table 60. Global Psoriasis Biosimilar Sales (K Units) by Application (2021–2026)
Table 61. Global Psoriasis Biosimilar Sales (K Units) by Application (2027–2032)
Table 62. Global Psoriasis Biosimilar Sales Market Share by Application (2021–2026)
Table 63. Global Psoriasis Biosimilar Sales Market Share by Application (2027–2032)
Table 64. Global Psoriasis Biosimilar Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Psoriasis Biosimilar Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Psoriasis Biosimilar Revenue Market Share by Application (2021–2026)
Table 67. Global Psoriasis Biosimilar Revenue Market Share by Application (2027–2032)
Table 68. Global Psoriasis Biosimilar Price (US$/Unit) by Application (2021–2026)
Table 69. Global Psoriasis Biosimilar Price (US$/Unit) by Application (2027–2032)
Table 70. Merck KGaA Company Information
Table 71. Merck KGaA Description and Business Overview
Table 72. Merck KGaA Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Merck KGaA Psoriasis Biosimilar Product
Table 74. Merck KGaA Recent Developments/Updates
Table 75. Gyros Protein Technologies AB Company Information
Table 76. Gyros Protein Technologies AB Description and Business Overview
Table 77. Gyros Protein Technologies AB Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Gyros Protein Technologies AB Psoriasis Biosimilar Product
Table 79. Gyros Protein Technologies AB Recent Developments/Updates
Table 80. Pfizer Inc. Company Information
Table 81. Pfizer Inc. Description and Business Overview
Table 82. Pfizer Inc. Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Pfizer Inc. Psoriasis Biosimilar Product
Table 84. Pfizer Inc. Recent Developments/Updates
Table 85. Novartis International AG Company Information
Table 86. Novartis International AG Description and Business Overview
Table 87. Novartis International AG Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Novartis International AG Psoriasis Biosimilar Product
Table 89. Novartis International AG Recent Developments/Updates
Table 90. Amgen Inc Company Information
Table 91. Amgen Inc Description and Business Overview
Table 92. Amgen Inc Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Amgen Inc Psoriasis Biosimilar Product
Table 94. Amgen Inc Recent Developments/Updates
Table 95. Samsung Bioepis Co., Ltd. Company Information
Table 96. Samsung Bioepis Co., Ltd. Description and Business Overview
Table 97. Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Product
Table 99. Samsung Bioepis Co., Ltd. Recent Developments/Updates
Table 100. Coherus BioSciences Company Information
Table 101. Coherus BioSciences Description and Business Overview
Table 102. Coherus BioSciences Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Coherus BioSciences Psoriasis Biosimilar Product
Table 104. Coherus BioSciences Recent Developments/Updates
Table 105. Hoffmann-La Roche Ltd Company Information
Table 106. Hoffmann-La Roche Ltd Description and Business Overview
Table 107. Hoffmann-La Roche Ltd Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Hoffmann-La Roche Ltd Psoriasis Biosimilar Product
Table 109. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 110. Celltrion Company Information
Table 111. Celltrion Description and Business Overview
Table 112. Celltrion Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Celltrion Psoriasis Biosimilar Product
Table 114. Celltrion Recent Developments/Updates
Table 115. Samsung Bioepis Company Information
Table 116. Samsung Bioepis Description and Business Overview
Table 117. Samsung Bioepis Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Samsung Bioepis Psoriasis Biosimilar Product
Table 119. Samsung Bioepis Recent Developments/Updates
Table 120. Sandoz Company Information
Table 121. Sandoz Description and Business Overview
Table 122. Sandoz Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Sandoz Psoriasis Biosimilar Product
Table 124. Sandoz Recent Developments/Updates
Table 125. Fresenius Kabi Company Information
Table 126. Fresenius Kabi Description and Business Overview
Table 127. Fresenius Kabi Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Fresenius Kabi Psoriasis Biosimilar Product
Table 129. Fresenius Kabi Recent Developments/Updates
Table 130. Viatris Company Information
Table 131. Viatris Description and Business Overview
Table 132. Viatris Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Viatris Psoriasis Biosimilar Product
Table 134. Viatris Recent Developments/Updates
Table 135. Reddy's Laboratories Company Information
Table 136. Reddy's Laboratories Description and Business Overview
Table 137. Reddy's Laboratories Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. Reddy's Laboratories Psoriasis Biosimilar Product
Table 139. Reddy's Laboratories Recent Developments/Updates
Table 140. GenScript Company Information
Table 141. GenScript Description and Business Overview
Table 142. GenScript Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. GenScript Psoriasis Biosimilar Product
Table 144. GenScript Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Psoriasis Biosimilar Distributors List
Table 148. Psoriasis Biosimilar Customers List
Table 149. Psoriasis Biosimilar Market Trends
Table 150. Psoriasis Biosimilar Market Drivers
Table 151. Psoriasis Biosimilar Market Challenges
Table 152. Psoriasis Biosimilar Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
Table 156. Authors List of This Report
List of Figures
Figure 1. Product Picture of Psoriasis Biosimilar
Figure 2. Global Psoriasis Biosimilar Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Psoriasis Biosimilar Market Share by Type: 2025 & 2032
Figure 4. TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab) Product Picture
Figure 5. Other Biosimilars Product Picture
Figure 6. Global Psoriasis Biosimilar Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Psoriasis Biosimilar Market Share by Application: 2025 & 2032
Figure 8. Plaque Psoriasis
Figure 9. Psoriatic Arthritis
Figure 10. Other
Figure 11. Global Psoriasis Biosimilar Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Psoriasis Biosimilar Market Size (US$ Million), 2021–2032
Figure 13. Global Psoriasis Biosimilar Sales (K Units), 2021–2032
Figure 14. Global Psoriasis Biosimilar Average Price (US$/Unit), 2021–2032
Figure 15. Psoriasis Biosimilar Report Years Considered
Figure 16. Psoriasis Biosimilar Sales Share by Manufacturers in 2025
Figure 17. Global Psoriasis Biosimilar Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Psoriasis Biosimilar Players: Market Share by Revenue in Psoriasis Biosimilar in 2025
Figure 19. Psoriasis Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Psoriasis Biosimilar Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Psoriasis Biosimilar Sales Market Share by Country (2021–2032)
Figure 22. North America Psoriasis Biosimilar Revenue Market Share by Country (2021–2032)
Figure 23. United States Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Psoriasis Biosimilar Sales Market Share by Country (2021–2032)
Figure 26. Europe Psoriasis Biosimilar Revenue Market Share by Country (2021–2032)
Figure 27. Germany Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Psoriasis Biosimilar Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Psoriasis Biosimilar Revenue Market Share by Region (2021–2032)
Figure 34. China Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Psoriasis Biosimilar Sales Market Share by Country (2021–2032)
Figure 42. Latin America Psoriasis Biosimilar Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Psoriasis Biosimilar Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Psoriasis Biosimilar Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Psoriasis Biosimilar Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Psoriasis Biosimilar by Type (2021–2032)
Figure 53. Global Revenue Market Share of Psoriasis Biosimilar by Type (2021–2032)
Figure 54. Global Psoriasis Biosimilar Price (US$/Unit) by Type (2021–2032)
Figure 55. Global Sales Market Share of Psoriasis Biosimilar by Application (2021–2032)
Figure 56. Global Revenue Market Share of Psoriasis Biosimilar by Application (2021–2032)
Figure 57. Global Psoriasis Biosimilar Price (US$/Unit) by Application (2021–2032)
Figure 58. Psoriasis Biosimilar Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
